3G0.F · Altimmune, Inc

-

Please sign in to comment on 3G0.F

1 Comment

Admin

3 years, 8 months ago

Altimmune, Inc is currently in a long term downtrend where the price is trading 37.1% below its 200 day moving average.

From a valuation standpoint, the stock is 96.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 43.0.

Altimmune, Inc's total revenue rose by 301.7% to $2M since the same quarter in the previous year.

Its net income has dropped by 159.3% to $-11M since the same quarter in the previous year.

Finally, its free cash flow fell by 574.4% to $-14M since the same quarter in the previous year.

Based on the above factors, Altimmune, Inc gets an overall score of 2/5.

Industry	Biotechnology
Sector	Healthcare
ISIN	US02155H2004
CurrencyCode	EUR
Exchange	F

Target Price	30.86
Beta	0.09
PE Ratio	None
Market Cap	205M
Dividend Yield	0.0%

ABOUT

Altimmune, Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

3G0.F · Altimmune, Inc

-

Altimmune, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Altimmune, Inc using a moving average strategy